Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:    
Research and development $ 8,765 $ 8,205
General and administrative 4,881 4,494
Total operating expenses 13,646 12,699
Operating loss (13,646) (12,699)
Other income:    
Other income, net 82 229
Governmental assistance - research incentives 0 205
Total other income, net 82 434
Loss before income tax expense (13,564) (12,265)
Income tax expense (28) (27)
Net loss (13,592) (12,292)
Other comprehensive loss    
Unrealized loss on marketable securities (49) (4)
Net loss and comprehensive loss $ (13,641) $ (12,296)
Basic and diluted net loss per share (in dollars per share) $ (0.65) $ (0.78)
Weighted average shares outstanding – basic and diluted (in shares) 20,773,399 15,680,320